Scientific Statement on Statin Intolerance: A New Definition and Key Considerations for ASCVD Risk Reduction in the Statin Intolerant Patient
Last Updated: Saturday, 04-Jun-2022 13:00:00 EDT
NLA Scientific Statement on Statin Intolerance: A New Definition and Key Considerations for ASCVD Risk Reduction in the Statin Intolerant Patient
Statin intolerance is defined as one or more adverse effects associated with statin therapy which resolve or improve with dose reduction or discontinuation and can be classified as a complete inability to tolerate any dose of a statin, or partial intolerance with inability to tolerate the dose necessary to achieve the patient-specific therapeutic objective.
Facts about Statins & Statin Intolerance
Statins are generally well tolerated.
Some degree of statin intolerance is reported in 5-30% of patients and contributes to reduced statin adherence and persistence, as well as higher risk for adverse cardiovascular outcomes.
Statin intolerance is a clinical syndrome that can manifest on a continuum. Some patients experience partial intolerance while others are completely intolerant.
Modifiable risk factors may contribute to statin intolerance symptoms and addressing the risk factor may improve statin tolerance in some instances.
Most patients can tolerate some degree of statin therapy (agent, dose and/or regimen) if they experience symptoms.
Authors: Mary Katherine Cheeley, PharmD, CLS, FNLA; Joseph J. Saseen, PharmD, FNLA, CLS; Anandita Agarwala, MD; Sudha Ravilla, MD, FNLA; Nicole Ciffone, MSN, ANP-C, CLS, FNLA; Terry A. Jacobson, MD, FNLA; Dave L. Dixon, PharmD, CLS, FNLA; Kevin C. Maki, PhD, CLS, FNLA